US FDA approves Marinus Pharmas lead drug to treat genetic disorder

The oral drug, which will be sold under the brand name Ztalmy, is intended specifically for treatment of seizures associated with CDKL5 deficiency disorder, a rare genetic epilepsy The US Food and Drug Administration has approved Marinus Pharmaceuticals Inc's lead drug to treat seizures associated with a rare genetic disorder in patients two years of age and older, the company said on Friday. The oral drug, which will be sold under the brand name Ztalmy, is intended specifically for treatment of seizures associated with CDKL5 deficiency disorder, a rare genetic epilepsy Pharma Marinus Pharma CDKL5 deficiency disorder Ztalmy U.S. FDA health news genetic disorder The regulatory approval was based on data from a late-stage study in 101 patients that showed a 30.7% median reduction in 28-day major motor seizure frequency in patients treated with the drug, as compared to a 6.9% decline in those receiving placebo. Marinus has priced the drug at about $133,000 per patient per year at the wholesale level, while after discounts, including for Medicaid patients, it will cost an average of $105,000 per patient per year, Chief Executive Officer Scott Braunstein told Reuters. At the wholesale level, the chronic medication translates to $2,425 per bottle, Braunstein said. Ztalmy is expected to be commercially available in the U.S. in July through a designated specialty pharmacy

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!